|
May 30
|
Danaher Corporation (DHR) Launches Partnership with AstraZeneca PLC (AZN) to Scale Next-Gen Precision Medicine Tests
|
|
May 29
|
Danaher Announces Diagnostic Development and Commercialization Partnership to Scale Precision Medicine
|
|
May 23
|
European Equities Close Sharply Lower in Friday Trading; German Q1 GDP Expands 0.4% Sequentially
|
|
May 23
|
Aptar Digital to use AstraZeneca’s AI algorithms for CKD detection
|
|
May 21
|
Are You a Growth Investor? This 1 Stock Could Be the Perfect Pick
|
|
May 21
|
The Zacks Analyst Blog Highlights Visa, AstraZeneca, Shell, Ocean Power Technologies and Wheeler Real Estate Investment Trust
|
|
May 21
|
AstraZeneca Stock Declines 6% in 3 Months: Time to Buy the Dip?
|
|
May 21
|
AstraZeneca’s record seventh year of plenary data at ASCO furthers ambition to redefine breast cancer care and transform outcomes in gastric cancer
|
|
May 21
|
3 Promising Growth Stocks You Can Buy for Less Than $100
|
|
May 20
|
Top Research Reports for Visa, AstraZeneca & Shell
|
|
May 20
|
AstraZeneca (LSE:AZN) Reports Positive AIRSUPRA Results Reducing Severe Asthma Risks
|
|
May 20
|
AstraZeneca says Airsupra reduced severe asthma risk by 47%
|
|
May 20
|
AstraZeneca PLC (AZN) Trial: Airsupra Cuts Severe Asthma Risk by 47%
|
|
May 19
|
Astrazeneca's Asthma Therapy Shows Improvement Across Primary and Secondary Endpoints in Late-Stage Trial
|
|
May 19
|
Statistically significant and clinically meaningful BATURA Phase III trial results provide new evidence for AIRSUPRA as standard of care for as-needed rescue treatment in asthma
|
|
Apr 25
|
The Zacks Analyst Blog Highlights Tempus AI, AstraZeneca, iRhythm Technologies and SOPHiA GENETICS
|
|
Apr 25
|
Stocks to watch next week: Apple, Microsoft, Shell, HSBC, Lloyds and AstraZeneca
|
|
Apr 24
|
Tempus AI Stock Sees 21% Gain in 3 Days: Is it a Buy After AZN Deal?
|
|
Apr 24
|
Unveiling Astrazeneca (AZN) Q1 Outlook: Wall Street Estimates for Key Metrics
|
|
Apr 24
|
AstraZeneca enters $200m AI cancer pact with Tempus and Pathos
|